Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

Total article views   HTML views PDF downloads Totals
22,894 Dovepress* 11,569+ 2,287 13,856
PubMed Central* 11,325 1,931 13,256
Totals 22,894 4,218 27,112
*Since 20 July 2018
Total mentioned Facebook Delicious Reddit Twitter Others
1 0 0 0 0 1

View citations on PubMed Central and Google Scholar